Artal Group’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,000,000
Closed -$11.2M 122
2023
Q4
$11.2M Hold
1,000,000
0.37% 32
2023
Q3
$11.7M Sell
1,000,000
-625,000
-38% -$7.07M 0.5% 31
2023
Q2
$16.4M Buy
1,625,000
+1,025,000
+171% +$9.17M 0.51% 29
2023
Q1
$4.43M Buy
+600,000
New +$4.94M 0.26% 63

Other funds holding ROIV

Artal Group's ROIV Position: Q1 2024 in Review

Artal Group sold out of Roivant Sciences (ROIV) in Q1 2024, closing a stake of 1,000,000 shares — an estimated $11.2M sold.

Artal Group first reported a position in ROIV in Q1 2023 and held it in 4 quarters. The position peaked at $16.4M in Q2 2023. 259 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

  • Artal Group reported no remaining Roivant Sciences position as of Q1 2024 after selling out during the quarter.
  • Artal Group sold 1,000,000 Roivant Sciences shares in Q1 2024, an estimated $11.2M.
  • Artal Group first reported a position in Roivant Sciences in Q1 2023 and held it in 4 quarters.
  • Artal Group's Roivant Sciences position peaked at $16.4M in Q2 2023.
  • 259 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.